StockData
AstraZeneca PLC logo

AstraZeneca PLC

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca Core R&D expense YoY CER by Quarter

Core R&D expense YoY CER (%) (%)

QuarterlyAnnual

AstraZeneca Core R&D expense YoY CER: 5.0% in Q2 2026, down 13.0 pts from a year earlier.

Latest, Q2 2026
5.0%
Period ended Jun 30, 2026
Change on a year earlier
-13.0 pts
18.0% in Q2 2025
History
23 quarters
Since Q4 2020
Sources
23
Documents cited below

Where the Q2 2026 figure comes from

“|| R&D expense | | (4,053) | | | 36 | | | 355 | | – | | (3,662) | 6 | 5”

Source: Form 6-K FY2026Q2 Earnings Release ↗

Reported in Form 6-K / 20-F Core Financial Measures.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedCore R&D expense YoY CER (%) (%)Year on yearSource
Q2 2026Jun 30, 20265.0%-13.0 ptsForm 6-K FY2026Q2 Earnings Release ↗
Q1 2026Mar 31, 20268.0%-8.0 ptsForm 6-K FY2026Q1 Earnings Release ↗
Q4 2025Dec 31, 20253.0%-19.0 ptsForm 6-K FY2025Q4 Earnings Release ↗
Q3 2025Sep 30, 202514.0%-10.0 ptsForm 6-K FY2025Q3 Earnings Release ↗
Q2 2025Jun 30, 202518.0%+5.0 ptsForm 6-K FY2025Q2 Earnings Release ↗
Q1 2025Mar 31, 202516.0%-2.0 ptsForm 6-K FY2025Q1 Earnings Release ↗
Q4 2024Dec 31, 202422.0%+8.0 ptsForm 6-K FY2024Q4 Earnings Release ↗
Q3 2024Sep 30, 202424.0%+19.0 ptsForm 6-K FY2024Q3 Earnings Release ↗
Q2 2024Jun 30, 202413.0%+5.0 ptsForm 6-K FY2024Q2 Earnings Release ↗
Q1 2024Mar 31, 202418.0%+8.0 ptsForm 6-K FY2024Q1 Earnings Release ↗
Q4 2023Dec 31, 202314.0%+2.0 ptsForm 6-K FY2023Q4 Earnings Release ↗
Q3 2023Sep 30, 20235.0%-11.0 ptsForm 6-K FY2023Q3 Earnings Release ↗
Q2 2023Jun 30, 20238.0%-32.0 ptsForm 6-K FY2023Q2 Earnings Release ↗
Q1 2023Mar 31, 202310.0%-26.0 ptsForm 6-K FY2023Q1 Earnings Release ↗
Q4 2022Dec 31, 202212.0%-28.0 ptsForm 6-K FY2022Q4 Earnings Release ↗
Q3 2022Sep 30, 202216.0%-30.0 ptsForm 6-K FY2022Q3 Earnings Release ↗

Cite this data

StockData. (2026). AstraZeneca Core R&D expense YoY CER (%), quarterly Q4 2020–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/core-rd-cer-yoy

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.